Thalidomide in the treatment of high-grade gliomas [4]

Journal of Clinical Oncology

Volumn 18, Issue 19, 2000, Pages 3453-

  Cohen, M H ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; POLYANHYDRIDE; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; GLIOBLASTOMA; GLIOMA; HUMAN; LETTER; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS, PHASE II; GLIOMA; HUMANS; MIDDLE AGED; THALIDOMIDE;

EID: 0034305980     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
2. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials
3. Prognostic factors for high-grade malignant glioma: Development of a prognostic index
4. Challenges in the design and conduct of phase llI brain tumor therapy trials
5. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas